Medications used in dementia: a review of evidence
C Suraweera, R Hanwella, VA de Silva

Background
Dementia is an acquired global impairment of intellect, memory and personality, without impairment of consciousness. It is usually progressive in nature. The management of dementia is mainly two faceted; pharmacological and non-pharmacological.

Aims
To review the evidence regarding the efficacy of cholinesterase inhibitors, memantine and antipsychotics, in the treatment of dementia.

Methods
We searched ALOIS, Cochrane database, PubMed, Scopus and Google scholar using key words; dementia, cognitive enhancers, cholinesterase inhibitors and memantine as individual words for relevant review articles.

Results
There is evidence of efficacy of donepezil, rivastigmine and galantamine in mild to moderate Alzheimer’s dementia (AD). Evidence also suggests that memantine has efficacy in moderate to severe AD. Further, memantine may benefit behavioural and psychological symptoms of dementia (BPSD), and has also being considered for the treatment of dementias of lesser severity.

Evidence also supports the use of AChE inhibitors in vascular dementia and dementia due to Parkinson’s disease (PDD). But evidence regarding efficacy in dementia of Lewy Body (DLB) is not very strong.

Antipsychotics can be used for the management of BPSD if other measures fail, keeping in mind the black box warning for the risk of stroke. The use of antidepressants and mood stabilisers are limited by the lack of strong evidence.

Conclusion
The current evidence supports the use of cholinesterase inhibitors and memantine in patients with Alzheimer’s dementia, vascular dementia and PDD, with a positive impact on global assessment, cognitive function, behavioural disturbance and activities of daily living rating scales. The effect in DLB remains unclear.

SL J Psychiatry 2015; 6(2): 3-8

Introduction
Dementia is an acquired global impairment of intellect, memory and personality, but without impairment of consciousness. It is usually progressive in nature. The pattern of cognitive impairment depends on the type and severity of dementia. Impairments of cognitive function are commonly accompanied, and occasionally preceded by, deterioration in emotional control, social behaviour, or motivation resulting in significant impairment in activities of daily living (1). The non-cognitive symptoms associated with dementia such as mood, psychotic and sleep-wake cycle disturbances – i.e., the behavioural and psychological symptoms of dementia (BPSD) – and are seen in about 50-80% of patients (2).

The two main classification systems used in the world to diagnose psychiatric illness are the Diagnostic and Statistical Manual of Mental Disorders – 5 (DSM-5) and the International Classification of Diseases (ICD-10) (1). The DSM-5, released in 2013, has replaced the word dementia with the term ‘major neurocognitive disorder (NCD)’ (3). Both the ICD-10 and DSM-5 require impairment in two or more cognitive domains, sufficient to cause difficulties in social and occupational functioning, for the diagnosis of dementia. Screening tests for dementia include the Mini Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA). More definitive tests for diagnostic and monitoring purposes of dementia include the Alzheimer’s Disease Assessment Scale (ADAS), Addenbrook’s Cognitive Assessment-Revised (ACE-R) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).

Alzheimer’s disease (AD) is the commonest type of dementia, accounting for about 50-60% of all dementias. The prevalence of AD is 1 to 2% at the age of 65, but the prevalence doubles every 5 years after that (4). Memory impairment is prominent although it is not the only cognitive domain that is affected (5). Vascular dementia (VaD) accounts for about 20-25% of all dementias. The management options include controlling of cerebrovascular and metabolic risk factors (5,6). The clinical features of dementia with Lewy bodies (DLB) and Parkinson’s disease with dementia (PDD) are similar. The diagnosis of PDD rests on the occurrence of dementia in
a person formally diagnosed with Parkinson’s disease at least 12-months previously. DLB accounts for 15-20% of cases of dementia. Characteristic symptoms are deterioration of attention and visuospatial abilities, fluctuations in cognition and attention, well-formed visual hallucinations with motor features of Parkinsonism (5).

The management of dementia is mainly two faceted; pharmacological and non-pharmacological. Both these approaches are utilised for the management of the two main symptom domains; cognitive and non-cognitive. Although not strictly disease modifying, cognitive enhancers are used to manage the cognitive symptoms while antipsychotics, antidepressants, benzodiazepines and mood stabilizers are used to treat non-cognitive symptoms.

Methods
We searched ALOIS (a comprehensive, open-access register of dementia studies), Cochrane database, PubMed, Scopus and Google scholar using key words: dementia, cognitive enhancers, cholinesterase inhibitors and memantine. Our review is based on review articles indexed in these databases and the RCTs included in the reviews. We did not record the number of articles or assess the quality of the articles as this is not a systematic review. Relevance of the articles were determined by careful scrutiny of the contents by all three authors.

Results
Cognitive enhancers
The principal class of medication used for the treatment of dementia is cognitive enhancers, which includes cholinesterase (AChE) inhibitors, such as donepezil, rivastigmine, galantamine, and N-Methyl-D-aspartate (NMDA) antagonists, such as memantine.

Acetylcholinesterase (AChE) inhibitors
The cholinergic hypothesis of AD attributes cognitive deterioration to progressive loss of cholinergic neurons and decreasing levels of acetylcholine (ACh) in the brain (7). The three AChE inhibitors used in mild to moderate AD are donepezil, rivastigmine and galantamine, of which donepezil and rivastigmine are available in Sri Lanka.

In Alzheimer’s disease a meta-analysis of 13 RCTs found that treatment for over 6 months produced improvements in cognitive function, of on average -2.7 points (95% CI -3.0 to -2.3) on the ADAS-cog scale. Most trials were on patients with mild-moderate dementia. Benefits were also seen on measures of Activities of Daily Living (ADL) and behaviour, with small effect sizes (5). The meta-analyses reported no significant differences in efficacy between different AChE (8-11), a finding that may have been influenced by the small effect sizes.

Although there is a scarcity of comparative data for definitive conclusions to be made, withdrawal rates due to adverse effects for donepezil ranged from 4%-16% (placebo 1%-7%), 7%-29% for rivastigmine (placebo 7%) and 7%-23% for galantamine (placebo 7-9%). The number needed to harm (NNH) was 12 (8).

Donepezil
A 12-week RCT of 468 patients reported that donepezil use was associated with statistically significant improvements compared to placebo. The mean drug-placebo differences, at end point for the groups receiving 5 mg/d and 10 mg/d of donepezil hydrochloride were, respectively, 2.5 and 3.1 units for the ADAS-cog (11, 12). Results from a Cochrane review suggest that donepezil results in statistically significant improvements for both 5 and 10 mg/day at 24 weeks compared with placebo on the ADAS-cog, with a 2.01 point and a 2.80 point reduction, respectively (9). A long-term placebo controlled trial of donepezil in 565 patients with mild-to-moderate AD found a small but significant benefit on cognition compared with placebo. This was reflected in a 0.8 point difference in the MMSE score (95% CI 0.5-1.2; P<0.0001) which was replicated in other similar trials (14, 43).

Rivastigmine
Studies for rivastigmine suggest an advantage of 2.6-4.9 points on the ADAS-cog over placebo (13). A Cochrane review found that, high-dose rivastigmine (6-12 mg daily) was associated with a 2-point improvement in cognitive function on the ADAS-cog and a 2.2-point improvement in ADL at 26 weeks over placebo. At lower doses (4 mg daily or lower), the differences were statistically significant for cognitive functions only (14). According to a 6-month, double-blind, placebo controlled RCT, Rivastigmine transdermal patch (9.5 mg/24 h) is as effective as the highest doses of oral formulations (15).

Galantamine
A 5-month placebo controlled study of 978 patients found that the galantamine-placebo differences on ADAS-cog were 3.3 points for the 16 mg/day group and 3.6 points for the 24 mg/day group (p < 0.001 versus placebo, both doses) (16). A Cochrane review of ten trials found treatment with galantamine was associated with a significantly greater proportion of subjects with improved or unchanged global rating scale rating (k = 8 studies), at all dosing levels except for 8 mg/d (17). Galantamine is marginally effective in patients with severe AD with MMSE scores of 5-12 points (18, 32).

Memantine
Memantine is a moderate-affinity, uncompetitive, voltage-dependent NMDA receptor antagonist. A number-needed-to-treat (NNT) analysis of memantine
showed a NNT of 3-8 (19). It is indicated for the treatment of moderate to severe AD, and has shown significant efficacy in improving symptoms in several large-scale, controlled clinical studies (20-23). Memantine may be effective in delaying worsening of clinical symptoms, and decreasing the emergence of BPSD (24-25). A meta-analysis done in 2007 of six individual phase III studies using a subgroup of patients with moderate to severe AD showed that the drug resulted in a statistically significant benefit in four domains: namely cognitive, functional, global, and behavioural domains. The meta-analysis also highlighted a significant improvement in ADL with memantine, compared to placebo (22). A meta-analysis in 2011 found no significant differences between memantine and placebo on any outcome for patients with mild AD, either on individual trial or when data were combined (ADAS-cog 0.17; P = 0.82) (25). Memantine appears to be well tolerated (27). However, caution is required in hepatic impairment and seizures. The most frequently reported adverse effects in placebo-controlled trials included agitation (7.5% memantine, 12% placebo), falls (6.8% versus 7.1%) and dizziness (6.3% versus 5.7%) (26).

**Combination treatment**

Of the combinations, AChE inhibitor and memantine combination is the best tolerated, although there is no clear evidence of superior efficacy (21,29). However, there is some evidence that combining memantine with AChE inhibitors may slow cognitive and functional decline compared with mono-therapy or no treatment in the long term (29).

**Statins in dementia**

Four RCT have assessed the efficacy of statins in Alzheimer’s or probable Alzheimer’s dementia. Most patients were already on AChE. Pooled data showed no significant benefit from statin as measured by the ADAS-Cog (mean difference -0.26, 95% confidence interval (CI) -1.05 to 0.52, p=0.51) (48).

**Vascular dementia**

Three trials with a total of 800 participants have assessed the use of rivastigmine in vascular dementia (49). The largest included 710 participants with vascular dementia (VaD), including those with subcortical and cortical forms of the disorder. Statistically significant improvement in cognitive response was seen with rivastigmine treatment at 24 weeks, but there was no global impression of change, and no improvement of non-cognitive measures. Two other trials, with 1378 participants, have reported statistically significant treatment effects in favour of galantamine compared with placebo in cognition, activities of daily living and behaviour (50). There is evidence for donepezil, rivastigmine and galantamine use in VaD (29-31). There is also evidence for the use of memantine in VaD (6).

**Parkinson’s disease with dementia and dementia with Lewy bodies**

RCTs have assessed the use of cholinesterase inhibitors in both Parkinson’s disease with dementia (PDD) and dementia with Lewy bodies (DLB) (33). Three trials have reported cholinesterase inhibitor treatment to be superior to placebo in PDD, as measured by the Clinical Global Impression of Change (CGIC) score of -0.38, favouring the cholinesterase inhibitors (95% CI -0.56 to -0.24, P < 0.0001). There was no statistically significant difference in the MMSE between the control and treatment groups for patients with DLB (33). Although there are some concerns about worsening or adverse responses when patients with DLB are exposed to memantine, a recent RCT found it to be mildly beneficial in terms of global clinical status and behavioural symptoms in patients with DLB (26).

**Treatment of behavioural and psychological symptoms of dementia**

Second generation antipsychotics (SGA) are as effective as first generation antipsychotics (FGA) for behavioural and psychological symptoms of dementia (BPSD) (34,40,45,46). Reviews and trials support the efficacy of olanzapine, risperidone, quetiapine, aripiprazole and amisulpride with no significant differences between treatment groups (34-36).

**Benzodiazepines**

Although widely used, benzodiazepines are not recommended as it is associated with cognitive decline and falls (37).

**Antidepressants**

Evidence suggests that depression, which is present in 30-50%, can be both a cause and consequence of AD. Reviews indicated that antidepressants (mainly SSRIs) not only showed efficacy in treating BPSD, but were also well tolerated (47,51). Two out of five studies of sertraline versus placebo and one study of sertraline versus haloperidol have shown benefit. Five studies have shown that citalopram is of more benefit compared to risperidone.

**Mood stabilisers/anticonvulsants**

RCTs of mood stabilisers in BPSD are only available for carbamazepine and valproate, although gabapentin, lamotrigine and topiramate have also been used (38). A literature review of anticonvulsants in BPSD found that although there are benefits, the evidence is insufficient to support routine use (39).

**Discussion**

This review examined the evidence regarding the use of medication in the treatment of dementia. The symptoms
of dementia can be classified into two broad groups – namely cognitive and non-cognitive. The review examined the effects of medication on both groups of symptoms. The interpretation of results in trials is difficult due to the factors involving the disease process itself as well as other confounders. Most trials were conducted on patients with mild to moderate dementia with MMSE scores of 10-26, which introduces a bias.

The main question clinicians need answered is ‘will medication halt or reverse the process of cognitive decline, and will this result in improved quality of life?’ The average annual rate of decline in untreated patients ranges from 6 to 12 points on the ADAS-cog. A 4-point change in the ADAS-cog score is considered clinically meaningful (42).

Patients are classified in to three groups depending on the response: ‘non-responders’, who continue to decline at the anticipated rate; ‘non-decliners’, who neither improve significantly nor decline; and ‘improvers’, who improve to a clinically relevant extent. Data from trials of 6-months duration indicate that of those with AD being treated with AChE inhibitors, 24-34% will be ‘improvers’, compared to only 16% who will be ‘improvers’ on placebo. Around 55-70% will be ‘non-decliners’ (40).

It was previously thought that treatment does not improve cognitive functions, merely halts cognitive decline. However recent RCTs indicate that cognitive functions in nearly one third of patients improve with treatment, and more than half are non decliners. Based on this evidence we recommend starting AChE in all patients diagnosed with mild-moderate AD. The duration of most trials is 24 weeks, although there is some evidence of benefit from longer trials. The data also shows that there is little to choose between the differences of AChE in terms of efficacy. So the choice is dependent on ease of dosing, tolerability, cost and availability (42).

The patient’s cognitive and functional status should be monitored over 6-month intervals, and pharmacologic therapy should ideally be continued until there are no meaningful social interactions and quality of life has irreversibly deteriorated.

With AChE, side effects such as nausea, vomiting, dizziness, insomnia and diarrhoea are due to excess cholinergic stimulation, which most likely occurs at the start of therapy or when the dose is increased. Donepezil appears to a better side effect profile according to clinical trials. However any significant difference between AChE inhibitors is yet to be identified. Gastrointestinal effects appeared to be more common with oral rivastigmine than with other AChE inhibitors, thus requiring slower titration. The cardiac adverse effects should be borne in mind when prescribing AChE inhibitors due to vagotonic effects.

There are other issues that clinicians need to consider; for instance, the treatment response with AChE inhibitors is lost when the medications are interrupted and may not be fully regained when it is reinitiated (42). And failure to benefit from one AChE inhibitor does not necessarily mean that a patient will not respond to another and poor tolerability to one agent does not rule out good tolerability to another (28).

Memantine is a NMDA receptor antagonist, which can be used in Sri Lanka under a personal license. Unlike AChE it is effective in moderate-severe AD. It is effective in treating cognitive decline and behavioural problems and may be better tolerated than AChE by some patients.

Most of the trials have been conducted in patients with Alzheimer’s dementia. It is important to know if these medications are effective in other types of dementia too. Vascular dementia is the second most common type of dementia after Alzheimer’s disease. In older patients in particular, the combination of vascular dementia and Alzheimer’s disease is common, and is referred to as mixed dementia. Evidence supports the use of AChE in vascular dementia (49, 50).

The currently available evidence supports the use of cholinesterase inhibitors in patients with PDD, with a positive impact on global assessment, cognitive function, behavioral disturbance and activities of daily living rating scales. The effect in DLB remains unclear (33).

Behavioral and psychological symptoms of dementia include agitation, depression, apathy, repetitive questioning, psychosis, aggression, sleep problems, wandering, and a variety of inappropriate behaviors (41). As dementia progresses treatment of behavioural and psychological symptoms become more difficult. First-generation antipsychotics (FGAs) which have been used for a long time for BPSD are being replaced by the second-generation antipsychotics (SGA), as they are better tolerated due to the absence of extra pyramidal side effects (45). However, their use is limited by controversial issues, such as small effect sizes, poor tolerability and possible association with increased mortality (45, 46). The reports of increase of stroke have led to a black box warning for the use of SGAs for BPSD. Therefore antipsychotics should be used with caution and for a limited period, where other methods such as behavioural modification have failed.

Recent data supports the efficacy of SSRI in treating depressive symptoms in dementia. Findings also suggest that in treatment of AD patients with cholinesterase inhibitors and SSRIs may offer some degree of protection against the adverse effects of depression on cognition (47). Tricyclic antidepressants are not recommended due to the poor side effects profile.

**Conclusion**

The currently available evidence supports the use of cholinesterase inhibitors and memantine in patients with Alzheimer’s dementia, vascular dementia and PDD, with a positive impact on global assessment, cognitive function, behavioural disturbance and activities of daily
living rating scales. Antipsychotics should be used with caution, when needed and when other treatment measures have failed. Antidepressants have shown to be useful in those patients with dementia who also have features of depression.

C Suraweera, Leicestershire Partnership NHS Trust, United Kingdom
R Hanwella, Department of Psychological Medicine, Faculty of Medicine, University of Colombo
VA de Silva, Department of Psychological Medicine, Faculty of Medicine, University of Colombo

Corresponding author: C Suraweera
Email: dr.chathurie@gmail.com
DOI http://dx.doi.org/10.4038/sljpysc.v6i2.8073

Declaration of interest
None declared

References

Sri Lanka Journal of Psychiatry Vol 6(2) December 2015


